Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)Yuankai Shi, Lin Wang, Jiuwei Cui et al.|Journal of Thoracic Oncology|2024Cited by 40
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Huaize Geng, Jian Fang et al.|Signal Transduction and Targeted Therapy|2022Cited by 35
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Xiaoyan Kang, Jianhua Chen et al.|BMC Medicine|2023Cited by 24